Yeast-Display pHLA Screening for TCR Antigen Identification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for determining the antigen specificity of T cells, particularly 'orphan' TCRs, are limited in sensitivity and scalability, hindering the identification of potential targets for cancer immunotherapy, autoimmunity, and infection.

Innovation Solution

The development of yeast-display libraries of peptide-human leukocyte antigen (pHLA) allows for the screening of T cell receptors to identify specific antigens, using techniques such as deep sequencing and machine-learning algorithms to predict peptide targets.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If traditional empirical testing of candidate antigens is used, then T cell antigen specificity can be determined, but the process is extremely time-consuming and low-throughput

Engineering Contradiction:

Improveantigen specificity determinationVSAvoidthroughput of antigen identification

Core Design Contradiction:

Measurement precisionVSProductivity

Solution Approach 1:

The patent uses yeast-display technology to create copies of peptide-HLA complexes on yeast cell surfaces. Each yeast cell displays a unique peptide sequence fused to HLA molecules, creating a library of 10^7-10^8 different peptide-HLA copies. This allows parallel testing of countless antigen candidates simultaneously, transforming a sequential empirical testing process into a high-throughput parallel screening system that can identify T cell antigens in days rather than years

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The yeast-display system serves multiple functions: it presents peptide-HLA complexes for TCR binding, enables flow cytometry-based detection, allows deep sequencing of peptide sequences, and facilitates affinity purification. This multi-functional platform replaces multiple separate experimental approaches with a single integrated system that simultaneously provides antigen identification, validation, and characterization

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If mass spectrometry is used for antigen isolation, then unbiased antigen identification is achieved, but large cell numbers (10^7 to 10^9) are required

Engineering Contradiction:

Improveunbiased antigen identificationVSAvoidcell number requirement

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent introduces yeast cells as an intermediary carrier that displays peptide-HLA complexes on their surfaces. Instead of requiring large numbers of antigen-presenting cells for mass spectrometry analysis, the system uses yeast as a mediator to present the same peptide-HLA targets in a format that can be detected by flow cytometry and purified by affinity methods. This intermediary approach maintains unbiased antigen identification while reducing cell number requirements from 10^7-10^9 to much lower quantities

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mass spectrometry-based detection mechanism with flow cytometry-based detection. Instead of using complex mass spectrometry instrumentation to identify antigens from large cell samples, the system uses fluorescently labeled TCRs detected by flow cytometry to identify and isolate antigen-specific T cells from smaller samples, then uses deep sequencing to determine the bound peptide sequences

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Measurement precision

If TCR-pMHC binding affinity is increased, then T cell activation sensitivity improves, but cross-reactivity may increase potentially leading to autoimmunity

Engineering Contradiction:

ImproveT cell activation sensitivityVSAvoidcross-reactivity and autoimmunity risk

Core Design Contradiction:

Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent examines the local interaction interface between TCR and peptide-HLA by identifying specific amino acid residues involved in binding. Through deep sequencing of selected peptides and structural analysis, the system characterizes the precise local contact points and binding determinants. This detailed local quality analysis allows understanding how specific residue interactions contribute to both affinity and specificity, enabling rational design of TCRs with optimized binding properties

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent systematically varies peptide sequence parameters to map the TCR recognition landscape. By testing mutant peptides with single or multiple amino acid substitutions, the system determines how changes in peptide sequence affect TCR binding affinity and specificity. This parameter change approach identifies critical residues that maintain high affinity while preserving specificity, and establishes design rules for engineering TCRs with improved activation sensitivity without excessive cross-reactivity

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250042969A1Antigen discovery for t cell receptors isolated from patient tumors recognizing wild-type antigens and potent peptide mimotopes

Publication Date: 2025.02.06 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

AI summary

Compositions and methods are provided for peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.